SEATTLE (AP) — Shares of Dendreon Corp. jumped Monday morning, after the prostate cancer therapy maker said it expects fourth-quarter product revenue to grow about 10 percent compared with the fall quarter. The Seattle company forecast quarterly product revenue of about $74.8 million , which is up from the $68 million it reported in November for the third quarter. The projected figure would still represent a drop of about 12 percent year-over-year, but it topped Wall Street's $72.8 million average estimate, according to FactSet. Dendreon did not say when it will report its full results for the quarter. The company said in November that it planned to eliminate about 150 jobs and cut $125 million in annual spending after it reported disappointing sales for its Provenge therapy. Dendreon posted a loss of $67.2 million , or 44 cents per share, for the three months that ended Sept. 30 . But the company also said then that more patients signed up for treatment in October than in any other month in 2013. Dendreon said Monday it continues to generate new physician interest in Provenge. It added 31 net new accounts for the prostate cancer therapy in the fourth quarter. Shares of Dendreon climbed 16 percent, or 49 cents , to $3.48 in Monday morning trading, while broader indexes were largely flat. The stock is still trading at about half of the $7.22 that it peaked at last February before sliding to bottom at $2.23 in October.
Most Popular Stories
- Obama Administration Releases Proposal to Regulate For-Profit Colleges
- Elizabeth Vargas' Husband Marc Cohn Addresses Rumors
- Keurig Adds Peet's coffee, Alters Starbucks deal
- U.S. to Relinquish Gov't Control Over Internet
- Quiznos Files for Chapter 11
- SoCalGas Reaches Record Spend on Diversity Suppliers
- U.S. Consumer Sentiment Falls in Early March
- Vybz Kartel Convicted of Murder
- Koch Brothers Step up Anti-Obamacare Campaign
- Is Malaysian Airlines Flight 370 in Andaman Sea?